LLY

748.08

-0.86%↓

JNJ

177.42

-0.37%↓

ABBV

217.75

-0.25%↓

UNH

347.95

-1.4%↓

AZN

78.06

-1.86%↓

LLY

748.08

-0.86%↓

JNJ

177.42

-0.37%↓

ABBV

217.75

-0.25%↓

UNH

347.95

-1.4%↓

AZN

78.06

-1.86%↓

LLY

748.08

-0.86%↓

JNJ

177.42

-0.37%↓

ABBV

217.75

-0.25%↓

UNH

347.95

-1.4%↓

AZN

78.06

-1.86%↓

LLY

748.08

-0.86%↓

JNJ

177.42

-0.37%↓

ABBV

217.75

-0.25%↓

UNH

347.95

-1.4%↓

AZN

78.06

-1.86%↓

LLY

748.08

-0.86%↓

JNJ

177.42

-0.37%↓

ABBV

217.75

-0.25%↓

UNH

347.95

-1.4%↓

AZN

78.06

-1.86%↓

Search

Incyte Corp

Chiusa

SettoreSettore sanitario

83.04 -0.07

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

82.65

Massimo

83.61

Metriche Chiave

By Trading Economics

Entrata

247M

405M

Vendite

163M

1.2B

P/E

Media del settore

20.463

35.664

EPS

1.16

Margine di Profitto

33.319

Dipendenti

2,617

EBITDA

324M

582M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+1.08% upside

Dividendi

By Dow Jones

Utili prossimi

28 ott 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

3.3B

17B

Apertura precedente

83.11

Chiusura precedente

83.04

Notizie sul Sentiment di mercato

By Acuity

43%

57%

165 / 371 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Bullish Evidence

Incyte Corp Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

15 set 2025, 22:39 UTC

Acquisizioni, Fusioni, Takeovers

CSL Agrees to Deal to Advance Coagulation Treatment, May Acquire Developer

15 set 2025, 16:43 UTC

I principali Market Mover

Strive Shares Sink on Board Disclosure; Bitcoin Treasury Strategy

15 set 2025, 16:42 UTC

I principali Market Mover

Helius Medical Tech Jumps on Funding to Launch Solana Treasury

15 set 2025, 16:35 UTC

I principali Market Mover

Chegg to Pay $7.5 Million to Settle FTC Claims Over Subscription Cancellation Process

15 set 2025, 23:46 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

15 set 2025, 23:46 UTC

Discorsi di Mercato

Nikkei May Rise as Fed Rate Cut Hopes Support Stocks -- Market Talk

15 set 2025, 23:34 UTC

Discorsi di Mercato

Gold Steady Ahead of FOMC Meeting, Major U.S. Economic Data -- Market Talk

15 set 2025, 22:48 UTC

Discorsi di Mercato

FOMC May Opt to Play Catch Up With Rate Cuts -- Market Talk

15 set 2025, 22:12 UTC

Acquisizioni, Fusioni, Takeovers

CSL Expects Commercial Launch in 2029

15 set 2025, 22:12 UTC

Acquisizioni, Fusioni, Takeovers

CSL Says VarmX to Receive Further Commercial Milestones Afterwards

15 set 2025, 22:11 UTC

Acquisizioni, Fusioni, Takeovers

CSL Says VarmX to Receive Payments of Up to $388 Million Up to Launch of VMX-C001

15 set 2025, 22:11 UTC

Acquisizioni, Fusioni, Takeovers

CSL to Have Right to Exercise Option Based on Phase 3 Data

15 set 2025, 22:10 UTC

Acquisizioni, Fusioni, Takeovers

CSL to Make Upfront Payment to VarmX of $117 Million for Exclusive Option to Acquire Company

15 set 2025, 21:16 UTC

Acquisizioni, Fusioni, Takeovers

Chord Energy: Assets Have a Low Avg NYMEX WTI Breakeven and Are Immediately Competitive for Capital

15 set 2025, 21:16 UTC

Acquisizioni, Fusioni, Takeovers

Chord Energy: Assets Have Significant Overlap With Existing Footprint, Setting the Stage for Long-Lateral Development

15 set 2025, 21:15 UTC

Acquisizioni, Fusioni, Takeovers

Chord Energy to Buy 48,000 Net Acres in the Williston Core

15 set 2025, 21:14 UTC

Acquisizioni, Fusioni, Takeovers

Chord Energy to Buy Assets in Williston Basin From Exxon's XTO Energy and Affiliates for $550M

15 set 2025, 20:50 UTC

Discorsi di Mercato

Auto & Transport Roundup: Market Talk

15 set 2025, 20:50 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

15 set 2025, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

15 set 2025, 19:29 UTC

Discorsi di Mercato

U.S. Natural Gas Gains on Warmer Weather Outlook -- Market Talk

15 set 2025, 19:14 UTC

Discorsi di Mercato

Attacks on Russia Lifts Oil Price Despite Shaky Fundamentals -- Market Talk

15 set 2025, 18:16 UTC

Discorsi di Mercato

Gold Powers to New High -- Market Talk

15 set 2025, 18:05 UTC

Discorsi di Mercato

Easing Autonomous Vehicle Regulations Will Begin Tesla's Next Chapter -- Market Talk

15 set 2025, 17:50 UTC

Acquisizioni, Fusioni, Takeovers

U.S. Reaches Outline of Deal With China Over TikTok -- 2nd Update

15 set 2025, 17:10 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

15 set 2025, 17:10 UTC

Discorsi di Mercato

S&P Expects Fed, BOC to Cut Rates -- Market Talk

15 set 2025, 16:52 UTC

Discorsi di Mercato

Copper Climbs as Traders Brace for U.S. Rate Cut -- Market Talk

15 set 2025, 16:20 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

15 set 2025, 16:20 UTC

Discorsi di Mercato
Utili

Auto & Transport Roundup: Market Talk

Confronto tra pari

Modifica del prezzo

Incyte Corp Previsione

Obiettivo di Prezzo

By TipRanks

1.08% in crescita

Previsioni per 12 mesi

Media 84 USD  1.08%

Alto 110 USD

Basso 60 USD

Basato su 19 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Incyte Corp - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

19 ratings

10

Acquista

8

Mantieni

1

Vendi

Punteggio Tecnico

By Trading Central

59.52 / 62.66Supporto e resistenza

A breve termine

Bullish Evidence

A termine intermedio

Bearish Evidence

A lungo termine

Bearish Evidence

Sentiment

By Acuity

165 / 371 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sopra la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Incyte Corp

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation
help-icon Live chat